Clinical trials: Stage 2 Hypertension
Adrenocortical Carcinoma
Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)
This study will investigate the safety and efficacy of Relacorilant in combination with Pembrolizumab for Patients with Adrenocortical Carcinoma which Produces Too Much Stress Hormone (Cortisol).
- Trial name
- NCT04373265
- Testing
- Relacorilant, Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Corcept Therapeutics
Diabetes Mellitus, Type 2, Hypertension
Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension
To compare the safety, tolerability, pharmacokinetic (PK) profile, and pharmacodynamic (PD) effects of 2 treatment regimens of IW-1973 tablet (40 mg per day) administered orally for 2 weeks to patients with stable type 2 diabetes…
- Trial name
- NCT03091920
- Testing
- IW-1973
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Cyclerion Therapeutics
Hypertension
Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide
This is a Post-Marketing Surveillance study evaluating the Efficacy, Tolerability and Safety of Olmesartan medoxomil 20 mg in combination with 12.5 MG of hydrochlorothiazide in subjects with mild to moderate essential hypertension
- Trial name
- NCT00796159
- Testing
- Olmesartan medoxomil
- Volunteers
- 1,723 people
- Sponsor
- Pfizer
Hypertension, Hyperlipidemia
A Study to Investigate Pharmacokinetic Drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin
This is a phase 1, open label, two-cohort, single-sequence, crossover study
- Trial name
- NCT02951962
- Testing
- Twynsta 80/5mg, Crestor 20mg
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Lung Diseases
A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD
This Phase 3, 2-part, open-label, multicenter study aims to demonstrate the safety and tolerability of L606 in patients with PAH or PH-ILD.
- Trial name
- NCT04691154
- Testing
- L606 inhalation suspension
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Liquidia Technologies, Inc.
Diabetes Mellitus, Type 2, Hypertension
A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension
To evaluate the impact of escalating doses of IW-1973 on endothelial function [using EndoPAT to measure fingertip small vessel pulse volume], blood pressure (BP), and heart rate.
- Trial name
- NCT02906579
- Testing
- IW-1973
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Cyclerion Therapeutics
Endothelial Dysfunction
A Phase 2, Pharmacokinetic (PK) Study of 6R-BH4 Alone or 6R-BH4 With Vitamin C in Subjects With Endothelial Dysfunction
This Phase 2, randomized, open-label, 2-treatment, 2-sequence, 2-period crossover, pharmacokinetic (PK) study will compare plasma concentrations of BH4 in subjects with endothelial dysfunction following 14 days of treatment by…
- Trial name
- NCT00532844
- Testing
- Sapropterin Dihydrochloride, Sapropterin Dihydrochloride and Vitamin C
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- BioMarin Pharmaceutical
Hypertension, Diabete Type 2
Clinical Trial to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in Patients With Essential Hypertension and Type II Diabetes Mellitus
This clinical trial is a randomized, active controlled, double blind, parallel, multi center, phase 3 study to evaluate the efficacy and safety of monotherapy group of HL1113R1 or HL1113R2 versus HL1113 (Fixed dose combination)…
- Trial name
- NCT07552389
- Testing
- Test group, Exploratory test group, Control group 1
- Where
- South Korea
- Volunteers
- 228 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Cushing's Syndrome
Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
Cushing's syndrome is a relatively rare disorder caused by prolonged exposure to high levels of the glucocorticoid hormone cortisol. Cushing's syndrome may result from elevated endogenous or exogenous sources of cortisol.
- Trial name
- NCT02804750
- Testing
- CORT125134
- Where
- 25 sites in United States, Hungary and 3 more
- Volunteers
- 35 people
- Sponsor
- Corcept Therapeutics
Open Angle Glaucoma, Ocular Hypertension
Equivalence Study of Dorzolamide 2% Eye Drops Solution
The study aims to prospectively prove the equivalence of the test product and the reference solution in lowering intraocular pressure in patients with open angle glaucoma and ocular hypertension.
- Trial name
- NCT00878917
- Testing
- Dorzolamide 2 % eye drops solution
- Where
- Germany
- Volunteers
- 32 people
- Sponsor
- Alfred E. Tiefenbacher (GmbH & Co. KG)
Stage II Hypertension
Candesartan Effect in Second Stage Arterial Hypertension
To compare the changes in mean sitting DBP from baseline after 4 weeks of therapy with either candesartan cilexetil/HCT combination therapy or candesartan cilexetil monotherapy regimen
- Trial name
- CAESAR (NCT00621153)
- Testing
- Candesartan Cilexetil, Hydrochlorothiazide
- Where
- South Korea
- Volunteers
- 214 people
- Sponsor
- AstraZeneca
Hypertension
An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension
Effect of increasing doses of olmesartan medoxomil and olmesartan medoxomil/hydrochlorothiazide on blood pressure in patients with hypertension
- Trial name
- NCT00185068
- Testing
- Olmesartan medoxomil, Olmesartan medoxomil/hydrochlorothiazide, Hydrochlorothiazide
- Where
- 16 sites in United States
- Volunteers
- 110 people
- Sponsor
- Daiichi Sankyo
Pulmonary Hypertension Associated With HFpEF
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
The purpose of this study is to assess the efficacy and safety of the study drug, levosimendan (given orally), compared to placebo in participants with pulmonary hypertension with heart failure with preserved left ventricular…
- Trial name
- LEVEL-2 (NCT07288398)
- Testing
- TNX-103
- Where
- 140 sites in United States, Argentina and 13 more
- Volunteers
- 540 people
- Sponsor
- Tenax Therapeutics, Inc.
Pulmonary Arterial Hypertension
Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants with Pulmonary Arterial Hypertension (PAH)
- Trial name
- NCT07441200
- Testing
- NS-863 Low Dose, NS-863 High Dose
- Where
- Japan
- Volunteers
- 135 people
- Sponsor
- NS Pharma, Inc.
Hypertension, Resistant Hypertension
A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension
A multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase II trial of VB19055 for 12 weeks in 240 adults with uncontrolled hypertension (including resistant hypertension).
- Conditions
- Hypertension, Resistant Hypertension, Uncontrolled Hypertension
- Trial name
- NCT07833098
- Testing
- VB19055 Dose A QD, VB19055 Dose B QD, VB19055 Dose C QD
- Where
- 24 sites in China
- Volunteers
- 240 people
- Sponsor
- Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Essential Hypertension
Clinical Trial to Evaluate the Antihypertensive Effect of AGSCT101 in Patient With Hypertension
The purpose of this study is to evaluate the antihypertensive effect of AGSCT101 tablet in patient with stage 1 to 2 essential hypertension.
- Trial name
- NCT01413048
- Testing
- Carvedilol 25mg, AGSCT101 12.5mg
- Where
- South Korea
- Volunteers
- 260 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
PAH
PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)
This is a multicenter double-blind, placebo-controlled study to evaluate the safety, efficacy and pharmacokinetics of 2 doses of CXA-10 on stable background therapy in 96 subjects 18 to 80 years of age with PAH.
- Trial name
- PAH (NCT03449524)
- Testing
- 75mg CXA-10, 150mg CXA-10
- Where
- 46 sites in United States, United Kingdom
- Volunteers
- 69 people
- Sponsor
- Complexa, Inc.
Hypertension
A Clinical Trial to Evaluate the Safety and Pharmacokinetics of AJU-C52H in Healthy Volunteers
To evaluate the safety and pharmacokinetic characteristics of AJU-C52H in healthy adults
- Trial name
- NCT05077462
- Testing
- C52R1M Tab. and C52R2 Tab., AJU-C52H
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- AJU Pharm Co., Ltd.
Glaucoma
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults with Primary Open Angle Glaucoma or Ocular Hypertension
- Trial name
- NCT07168902
- Testing
- BL1107 Low dose, BL1107 High dose, Timolol maleate 0.5%
- Where
- 14 sites in United States
- Volunteers
- 252 people
- Sponsor
- Bausch & Lomb Incorporated
Hypertension
Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension
This study will compare the efficacy and safety of once daily dosing of aliskiren monotherapy to once daily dosing of aliskiren and hydrochlorothiazide combination therapy in patients with Stage II hypertension over a period of…
- Trial name
- ACQUIRE (NCT00705575)
- Testing
- Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg), Aliskiren (300 mg)
- Where
- 8 sites in United States, Argentina and 6 more
- Volunteers
- 688 people
- Sponsor
- Novartis